Goldman Sachs Access U.S. Aggregate Bond ETF (GCOR)
- Previous Close
40.02 - Open
40.09 - Bid 36.24 x 800
- Ask 43.94 x 900
- Day's Range
40.05 - 40.14 - 52 Week Range
37.59 - 42.45 - Volume
33,864 - Avg. Volume
95,600 - Net Assets 430.24M
- NAV 40.10
- PE Ratio (TTM) --
- Yield 3.80%
- YTD Daily Total Return -3.33%
- Beta (5Y Monthly) 1.02
- Expense Ratio (net) 0.14%
The fund seeks to achieve its investment objective by investing at least 80% of its assets (exclusive of collateral held from securities lending) in securities included in its underlying index. The index is a rules-based index that is designed to measure the performance of investment grade, U.S. dollar (“USD”)-denominated bonds issued in the United States that meet certain liquidity and fundamental screening criteria.
Goldman Sachs
Fund Family
Intermediate Core Bond
Fund Category
430.24M
Net Assets
2020-09-08
Inception Date
Performance Overview: GCOR
Trailing returns as of 4/26/2024. Category is Intermediate Core Bond.
People Also Watch
Holdings: GCOR
Top 1 Holdings (5.50% of Total Assets)
Related ETF News
Research Reports: GCOR
Analyst Report: Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingPrice TargetAnalyst Report: Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
RatingPrice TargetAnalyst Report: EOG Resources, Inc.
EOG Resources is an oil and gas producer with acreage in several US shale plays, primarily in the Permian Basin and the Eagle Ford. At the end of 2023, it reported net proven reserves of 4.5 billion barrels of oil equivalent. Net production averaged roughly 985,000 barrels of oil equivalent per day in 2023 at a ratio of 71% oil and natural gas liquids and 29% natural gas.
RatingPrice TargetAnalyst Report: Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice Target